PTC Therapeutics reported top-line results from a 24-month interim analysis of votoplam in the long-term extension portion of the Phase II Pivot-HD program. The company said the results showed favorable, dose-dependent effects on disease progression in stage 2 (early intermediate) Huntington’s patients compared with an external natural-history cohort. Votoplam (PTC-518) is an oral pre-mRNA splicing modifier being studied with a long-term extension approach after the original Pivot-HD trial met its primary endpoint at 12 weeks on blood huntingtin protein lowering. PTC noted that partner Novartis has a Phase III trial ongoing. The update comes as Huntington’s pipeline decisions increasingly rely on durability and functional trajectory data rather than short-term biomarker shifts. A longer time horizon can reshape the perceived risk profile for next development steps. The interim readout was framed by PTC as “favorable,” though the study design relative to external historical controls will likely remain a focal point for investors and clinicians.